Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers

Daria R Bulanova¹, Mikko Helenius¹, Anna P Sokolenko^{2

3}, Sergey G Kuznetsov¹, Evgeny N Imyanitov^{2

3

4

5}

Affiliations

¹ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
² Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg, Russia.
³ Department of Medical Genetics, Saint Petersburg Pediatric Medical University, Saint Petersburg, Russia.
⁴ Department of Oncology, I.I. Mechnikov North-Western Medical University, Saint Petersburg, Russia.
⁵ Department of Oncology, Saint Petersburg State University, Saint Petersburg, Russia.

PMID: 30474109
DOI: 10.1002/ijc.32013

Comment

Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers

Daria R Bulanova et al. Int J Cancer. 2019.

. 2019 Apr 1;144(7):1758-1760.

doi: 10.1002/ijc.32013. Epub 2019 Jan 6.

Authors

Daria R Bulanova¹, Mikko Helenius¹, Anna P Sokolenko^{2

3}, Sergey G Kuznetsov¹, Evgeny N Imyanitov^{2

3

4

5}

Affiliations

¹ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
² Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg, Russia.
³ Department of Medical Genetics, Saint Petersburg Pediatric Medical University, Saint Petersburg, Russia.
⁴ Department of Oncology, I.I. Mechnikov North-Western Medical University, Saint Petersburg, Russia.
⁵ Department of Oncology, Saint Petersburg State University, Saint Petersburg, Russia.

PMID: 30474109
DOI: 10.1002/ijc.32013

Erratum in

Erratum.
[No authors listed] [No authors listed] Int J Cancer. 2019 Aug 1;145(3):E16. doi: 10.1002/ijc.32241. Epub 2019 Mar 14. Int J Cancer. 2019. PMID: 31168825 No abstract available.

No abstract available

PubMed Disclaimer

Comment on

The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
Klaschik K, Hauke J, Neidhardt G, Tränkle C, Surowy HM, Heilmann-Heimbach S, Rappl G, Mangold E, Arnold N, Niederacher D, Sutter C, Burwinkel B, Engel C, Wappenschmidt B, Meindl A, Ernst C, Weber-Lassalle K, Weber-Lassalle N, Schmidt S, Borde J, Schmutzler RK, Hahnen E, Pohl-Rescigno E. Klaschik K, et al. Int J Cancer. 2019 Apr 1;144(7):1761-1763. doi: 10.1002/ijc.32016. Epub 2019 Jan 6. Int J Cancer. 2019. PMID: 30474284 No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers

Affiliations

Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers

Authors

Affiliations

Erratum in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous